HOME >> MEDICINE >> NEWS
American Chemical Society spotlights medicine, museums and mileage at Washington Meeting August 20-24

New findings about a weight-loss nutritional supplement, threats to America's museum treasures and a high-performance gasoline additive that reduces pollution will be presented August 20-24 at the 220th national meeting of the American Chemical Society, the world's largest scientific society with 161,000 members. The meeting will be held in Washington, D.C., at the Washington Convention Center and surrounding hotels.

More than 5,500 research papers will be presented to the 10,000 scientists expected to attend. As more information about their presentations becomes available, it will be posted on the World Wide Web, on an embargoed basis, at www.eurekalert.org under the "ACS 220th national meeting" button. Advisories and news releases will be posted at www.acs.org after the embargo is lifted.

The meeting is open to accredited news media. To register contact ACS at newsroom@acs.org . If you have questions, you may contact Charmayne Marsh at y_marsh@acs.org or 202-872-4445. Hotel reservations can be made through ACS at http://www.acs.org/meetings/washington2000/housing.html until Friday, July 28.

In conjunction with this meeting, ACS is inviting reporters to a special master class on the chemistry of dietary supplements, where chemists and researchers will discuss the science underlying a major conference presentation in a symposium on conjugated linoleic acids. Speakers will delve into such issues as analysis of the contents of dietary and herbal supplements, effectiveness and potential health threats, and related regulatory concerns. The class will be held the afternoon of Friday, August 18, the day before the meeting starts. To register, you may contact Charmayne Marsh and you may also contact the ACS Office of Communications at '"/>

Contact: Charmayne Marsh
y_marsh@acs.org
202-872-4445
American Chemical Society
17-Jul-2000


Page: 1 2

Related medicine news :

1. Consumers with disabilities empowered by American Disabilities Act
2. Definition of persistent vegetative state available from American Academy of Neurology
3. African-American women with endometrial cancer have more aggressive cancer than Caucasian women
4. New colorectal cancer screening recommendations for African Americans
5. American Thoracic Society Journal news tips for March 2005 (second issue)
6. Community care tops medical care at preventing heart disease in black Americans
7. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
8. Obesity among African-American stroke survivors increases risk factors for recurrent stroke
9. Awards & fellowships at the International & American Association for Dental Research General Session
10. American Academy of Neurology presents 57th Annual Meeting in Miami Beach
11. News tips from the 2005, 54th Annual Scientific Sessions of the American College of Cardiology

Post Your Comments:
(Date:6/19/2013)... A University of Iowa study reveals significant disparities ... for completing substance abuse treatment programs. Moreover, these ... , "Our findings suggest that for most states ... professor of psychiatry and biostatistics. "There are strong ... able to complete substance abuse treatment programs successfully, ...
(Date:6/19/2013)... Nearly 70 percent of Americans are on ... half take two, Mayo Clinic researchers say. Antibiotics, ... their study found. Twenty percent of patients are ... the findings, published online in the journal ... audio and video of Dr. Jennifer St. Sauver ...
(Date:6/19/2013)... pharmaceutical companies, along with the Japanese government and ... commitment to bolster Japan,s contribution to global health ... Fund), at a press conference held as a ... on African Development (TICAD V). , Representatives from ... of Health, Labour and Welfare, the Ministry of ...
(Date:6/19/2013)... PREFERRED Therapy Providers, Inc. (PREFERRED) has announced an ... a new Medicare Advantage Plan for PREFERRED’s provider network ... Arizona counties. The agreement takes effect in two stages: ... and Maricopa and Pima counties will become effective on ... of WellCare of Arizona has Medicare Advantage plans in ...
(Date:6/19/2013)... Guests at the Residence Inn Scottsdale Paradise Valley ... don’t go to bed or rise early thanks to a ... , Crafty travelers will have a little extra change ... Scottsdale Paradise Valley hotel’s Book Early and Save Up ... advance notice, guests can enjoy the year-round Scottsdale sunshine in ...
Breaking Medicine News(10 mins):Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 3Health News:PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4
(Date:6/19/2013)... June 19, 2013   Voices Against Brain Cancer ... cure for brain cancer, today announced that it has ... support the clinical investigation of Toca 511 & Toca ... glioma brain cancer (Grade 3 or Grade 4).  Tocagen ... for advanced cancer, with an initial focus on brain ...
(Date:6/19/2013)...   Nektar Therapeutics (Nasdaq: NKTR ) ... (HAL) study for NKTR-181, a first-in-class, opioid analgesic ... This slow rate of entry is designed to reduce the ... to current opioid analgesics. 1 In the study data ... placebo in "drug liking" and "feeling high" scores and had ...
(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
Breaking Medicine Technology:Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6
Cached News: